Immunotherapy before kidney surgery for high-risk kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before surgery for high-risk kidney cancer that has not spread. The goal is to see if the drugs can help reduce the risk of the cancer coming back or spreading in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and are scheduled to have surgery to remove your kidney (nephrectomy) for clear cell renal cell carcinoma, a type of kidney cancer.
- Your kidney cancer is considered high risk (meaning there is a high chance it could spread) but has not yet spread to other parts of your body.
- You have not had any prior treatment for kidney cancer, including immunotherapy (medicines that help your immune system fight cancer).
- You are healthy enough to safely wait about 9 weeks before your kidney surgery.
- You must have good organ function, such as normal blood cell counts and kidney/liver function, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests two drugs, lenvatinib and pembrolizumab, given before surgery to shrink kidney cancer that has spread into the large vein carrying blood to the heart (the vena cava). The goal is to see if this approach makes surgery more effective and improves outcomes.
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This study tests a new immunotherapy drug (cemiplimab), either alone or combined with another drug (fianlimab), after targeted radiation (SBRT) to kill cancer cells. It is for people with advanced clear cell kidney cancer who have few spots of spread and have not had many prior treatments.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.